Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arbind Chaudhary

Cardiovascular Disease Green Bay, WI Medical Doctor

NPI 1801150339 CMS profile 354308

744 S Webster Ave, Green Bay, WI 54301

Open in the dashboard

General payments

$42,358

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arbind Chaudhary of Green Bay, WI is reported in the CMS Open Payments database as having received $42,358 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,571 8
2024 General $3,449 34
2023 General $18,958 51
2022 General $18,309 40
2020 General $64 4
2019 General $7 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arbind Chaudhary
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Arbind Chaudhary were reported at $1,571. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Arbind Chaudhary Cardiovascular Disease median Middle half National median
2019 $7 $450 $127–$1,392 $163
2020 $64 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $18,309 $395 $121–$1,211 $149
2023 $18,958 $443 $136–$1,283 $160
2024 $3,449 $450 $136–$1,323 $164
2025 $1,571 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $14,555 30 payments
  2. Medtronic, Inc. $12,445 13 payments
  3. Abbott Laboratories $9,131 30 payments
  4. Biosense Webster, Inc. $2,863 34 payments
  5. Medical Device Business Services, Inc. $2,386 14 payments
  6. Biotronik Inc. $712 8 payments
  7. Shockwave Medical, Inc $147 1 payment
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $37 4 payments
  9. Novartis Pharmaceuticals Corporation $30 1 payment
  10. Cardiva Medical, Inc. $23 1 payment
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $24,928 7 payments
  2. Travel and Lodging $9,534 29 payments
  3. Food and Beverage $7,025 96 payments
  4. Education $871 6 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $5,117 43 payments
  2. EMBLEM MRI S-ICD $3,750 1 payment
  3. General - Therapies $3,038 11 payments
  4. ENSITE PRECISION $3,018 24 payments
  5. VersaCross Access Solution $2,615 12 payments
  6. NRG RF Transseptal Kit $988 2 payments
  7. OCTARAY MAPPING CATHETER $684 10 payments
  8. NUVISION ICE CATHETER $512 8 payments
  9. Acticor 7 VR-T DX $329 5 payments
  10. ENSITE $321 3 payments
  11. Other $1,344 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

185

Median for Cardiology: 2,533

Drug cost

$70,572

Median for Cardiology: $485,213

Branded share of claims

36.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 56 $63,532
Dofetilide Generic 17 $5,440
Metoprolol Succinate Generic 45 $794
Amiodarone Hcl Generic 37 $459
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 12 $224
Omeprazole Generic 18 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$20,269

Medicare's payments for the services billed

Medicare patients

290

Average age 77

Services billed

349

113 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 69%
Ischemic heart disease 51%
Heart failure 49%
Arthritis 46%
Diabetes 37%
Chronic kidney disease 36%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record